Clinical Trial

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-07-24
notable Primary completion pushed: 2026-10-01 -> 2027-04-30 2026-07-24
minor Completion pushed: 2026-10-01 -> 2027-04-30 2026-07-24
Trial Details
NCT Number NCT07496463
Lead Sponsor Massachusetts General Hospital
Conditions Pseudohypoparathyroidism Type 1a, Obesity
Enrollment 1 participants
Start Date 2026-07-21
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23